This course has expired. View available courses.
Oncology
Clinical Brief Series: Adjuvant immunotherapy for melanoma
Adjuvant immunotherapy has recently become a treatment option for patients with melanoma and sentinel lymph node biopsy (SLNB) plays a critical role in identifying the subset of patients at high risk of recurrence or relapse following complete resection who may benefit.
This 4-part series explores the latest clinical evidence and recommendations for adjuvant immunotherapy in patients with completely resected Stage III/IV melanoma, discusses which patients are appropriate for SLNB, what this procedure involves and how the results of SLNB should guide adjuvant therapy.
It also explores practical aspects of care with a focus on the importance of early identification and contains a case study.
This program is supported by an independent educational grant provided from Bristol Myers Squibb.
DURATION
1h
PROFESSION
Physician
# OF CREDITS
2
ACCREDITATION
RACGP CPD Program
EXPIRY DATE
2022-03-18
Adjuvant immunotherapy has recently become a treatment option for patients with melanoma and sentinel lymph node biopsy (SLNB) plays a critical role in identifying the subset of patients at high risk of recurrence or relapse following complete resection who may benefit.
This 4-part series explores the latest clinical evidence and recommendations for adjuvant immunotherapy in patients with completely resected Stage III/IV melanoma, discusses which patients are appropriate for SLNB, what this procedure involves and how the results of SLNB should guide adjuvant therapy.
It also explores practical aspects of care with a focus on the importance of early identification and contains a case study.
This program is supported by an independent educational grant provided from Bristol Myers Squibb.
Faculty
A/Prof Victoria Atkinson,
Medical Oncologist, Senior Staff Specialist, Princess Alexandra Hospital, QLD
Dr Lisa Beecham,
General Practitioner, Robina Town Medical Centre, QLD
Learning objectives
On completion of this program, participants will be able to:
- Recall the latest clinical evidence and recommendations on the role of adjuvant immunotherapy in patients with completely resected Stage III/IV melanoma
- Describe the evidence for initial excisional biopsy removal of possible melanoma lesions
- Describe the role of sentinel lymph node biopsy (SLNB) in identifying patients at high risk of recurrence or relapse following complete resection of melanoma, who may benefit from adjuvant immunotherapy
- Incorporate into current practice a systematic approach for identifying patients with melanoma who should be referred to a surgeon for SLNB
- Outline the ways in which a multidisciplinary team approach can improve outcomes for patients with melanoma
Accreditation
This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.
Activity no. 227975
Members are able to claim CPD activity points for 2 points through 'Quick log' on their RACGP CPD Dashboard.
# of credits: 2
Duration: 1h
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
